(July 25, 2024, 12:05 PM EDT) -- WASHINGTON, D.C. — A patent examiner failed to show that claims for an implant that releases a monoclonal antibody tissue to treat macular degeneration were obvious in light of prior art because the examiner failed to show that a combination of the prior art would result in the same type of continuous release describes by the patent claims at issue, a Patent Trial and Appeal Board (PTAB) panel found July 24....